Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Vera Therapeutics was founded in San Francisco in 2016 and in-licensed atacicept in 2020 [3] - The company aims to lead a paradigm shift in modulating the immune system to alleviate disease burdens [1] Product Information - Atacicept is a first-in-class dual BAFF April inhibitor, designed to control autoimmune disease activity while minimizing immune suppression challenges [3] - Positive Phase III results were reported last year, leading to the submission of a Biologics License Application (BLA) to the U.S. FDA [3] - The FDA has awarded priority review for atacicept, with a Prescription Drug User Fee Act (PDUFA) date set for July 7, 2026 [3]